Canaccord Genuity Reiterates a 'Buy' on InterMune (ITMN); Strong German Esbriet Rollout As Pricing Process Continue
ITMN Hot Sheet
Rating Summary:10 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Canaccord Genuity reiterates a 'Buy' on InterMune (NASDAQ: ITMN) price target of $23.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Esbriet (pirfenidone) potential for blockbuster worldwide sales, US clinical success. We still see major Esbriet EU commercial potential despite volatility on pricing concerns. Esbriet is ITMN’s drug for idiopathic pulmonary fibrosis (IPF), an orphan lung disease. We think Esbriet will see modest but encouraging 2012 adoption, EU peak sales of $730M and worldwide peak sales of nearly $4B."
"We still see strong Esbriet pricing arguments for Germany and the rest
of Europe: we do not share market’s concern. We continue to believe
orphan status gives Esbriet a solid pricing argument in the AMNOG
process."
For an analyst ratings summary and ratings history on InterMune click here. For more ratings news on InterMune click here.
Shares of InterMune closed at $15.41 yesterday, with a 52 week range of $10.67-$51.71.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Ritu Baral, said, "Reiterate rating and price target on Esbriet (pirfenidone) potential for blockbuster worldwide sales, US clinical success. We still see major Esbriet EU commercial potential despite volatility on pricing concerns. Esbriet is ITMN’s drug for idiopathic pulmonary fibrosis (IPF), an orphan lung disease. We think Esbriet will see modest but encouraging 2012 adoption, EU peak sales of $730M and worldwide peak sales of nearly $4B."
"We still see strong Esbriet pricing arguments for Germany and the rest
of Europe: we do not share market’s concern. We continue to believe
orphan status gives Esbriet a solid pricing argument in the AMNOG
process."
For an analyst ratings summary and ratings history on InterMune click here. For more ratings news on InterMune click here.
Shares of InterMune closed at $15.41 yesterday, with a 52 week range of $10.67-$51.71.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: InterMune (ITMN) to Divest ActImmune for $55M in Cash, Plus Two-Year Royalty Stream
- Barclays maintains an 'Equalweight' on Tech Data (TECD); Slight Adjustments on Q1 Results
- InterMune's (ITMN) Esbriet Survey Results Favorable - Goldman Sachs
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
